RT Journal Article
SR Electronic
T1 Two founder variants account for over 90% of pathogenic BRCA alleles in Orkney and Shetland
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.03.24305239
DO 10.1101/2024.04.03.24305239
A1 Kerr, Shona M.
A1 Klaric, Lucija
A1 Muckian, Marisa D.
A1 Cowan, Emma
A1 Snadden, Lesley
A1 Tzoneva, Gannie
A1 Shuldiner, Alan R.
A1 Miedzybrodzka, Zosia
A1 Wilson, James F.
YR 2024
UL http://medrxiv.org/content/early/2024/04/06/2024.04.03.24305239.abstract
AB For breast and ovarian cancer risk assessment in the isolated populations of the Northern Isles of Orkney and Shetland (in Scotland, UK) and their diasporas, quantifying genetically drifted BRCA1 and BRCA2 pathogenic variants is important. Two actionable variants in these genes have reached much higher frequencies than in cosmopolitan UK populations. Here, we report a BRCA2 splice acceptor variant, c.517-2A>G, found in breast and ovarian cancer families from Shetland. We investigated the frequency and origin of this variant in a population-based research cohort of people of Shetland ancestry, VIKING I. The variant segregates with female breast and ovarian cancer in diagnosed cases and is classified as pathogenic. Exome sequence data from 2,108 participants with three or more Shetlandic grandparents in VIKING I was used to estimate the population prevalence of c.517-2A>G in Shetlanders. Nine VIKING I research volunteers carry this variant, on a shared haplotype (carrier frequency 0.4%). This frequency is ∼130-fold higher than in UK Biobank, where the small group of carriers has a different haplotype. Records of birth, marriage and death indicate genealogical linkage of VIKING I carriers to a founder from the Isle of Whalsay, Shetland, similar to our observations for the BRCA1 founder variant from Westray, Orkney. In total, 93.5% of pathogenic BRCA variant carriers in Northern Isles exomes are accounted for by these two drifted variants. We thus provide the scientific evidence of an opportunity for screening people of Orcadian and Shetlandic origins for each drifted pathogenic variant, particularly women with Westray or Whalsay ancestry.Competing Interest StatementAS and GT are employees and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals.Funding StatementThis study was funded by the MRC University Unit award to the MRC Human Genetics Unit, University of Edinburgh, MC_UU_00007/10 and a Wellcome Trust Institutional Translational Partnership Award (University of Edinburgh 222060/Z/20/Z -PIII031). LK was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The South East Scotland Research Ethics Committee of NHS Lothian gave ethical approval for this work, reference 19/SS/0104.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll research data produced in the present study are available from accessQTL{at}ed.ac.uk on reasonable request, via managed access, following approval by the Data Access Committee and in line with the consent given by participants.